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Summary Cytogenetic and enzymatic studies have shown that chronic myeloid leukaemia (CML) represents
the clonal proliferation of a pluripotent stem cell. The Philadelphia chromosome (Ph') is the characteristic
karyotypic abnormality seen in this disease, although the exact role of this clonal marker in the pathogenesis
of CML is uncertain. At a molecular level, the Ph' has recently been shown to represent the translocation of
c-abl to a limited region (breakpoint cluster region, bcr) on chromosome 22. We have used probes for the bcr
gene to obtain molecular evidence for the clonal origin of blast crisis in 2 patient with CML. In both cases,
the first with myeloid and the second with lymphoid blast crisis, there was rearrangement of the bcr gene. The
patterns of rearrangement varied between patients but were identical when comparing acute and chronic
phases within the same individual. As the Ph' translocation is thought to represent a random recombination
event, these data not only provide further evidence for the clonal origin of blast crisis in CML, but also
suggest that in the second patient this translocation event had already occurred at the level of the pluripotent
stem cell.
Chronic myeloid leukaemia (CML) represents the
clonal proliferation of a pluripotent stem cell
capable of differentiation into several haemopoietic
cell types (Greaves et al., 1979). These include the
granulocytic, monocytic, erythroid, platelet, and
lymphoid cell lineages (Fialkow et al., 1977). Two
lines of evidence support this statement. Firstly, in
patients heterozygous for the X-linked isoenzyme,
glucose-6-phosphate dehydrogenase (G6PD),
involved tumour cells of varying lineages expressed
a single, common G6PD allele (Fialkow et al.,
1977). Secondly, in over 95% of cases, cytogenetic
studies have identified the Philadelphia
chromosome (Ph') - a consistent karyotypic
abnormality seen in both the chronic and acute
phases of this disease (Rowley & Testa, 1983).
Fialkow has suggested that this cytogenetic marker
is a secondary event occurring in an already
transformed haemopoietic stem cell (Fialkow et al.,
1981), although more recent evidence suggests that
the Philadelphia abnormality may be critical in the
pathogenesis of CML (Adams, 1985).
Using banding techniques, Rowley (1973) first
demonstrated that the Philadelphia chromosome
resulted from a reciprocal translocation between
chromosomes 9 and 22, i.e. t(9; 22). However
recently, molecular studies have determined that the
critical genetic event underlying this karyotypic
abnormality is the translocation (to chromosome
22) of the Abelson proto-oncogene c-abl, normally
located on chromosome 9 (de Klein et al., 1982).
The breakpoint region (bcr) on chromosome 22 has
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been cloned from one CML cell line and
subsequent analysis of 17 patients with CML has
revealed that in each case, the breakpoints were
clustered within a 5.8 kilobase (kb) - pair segment
(Groffen et al., 1984).
We have used a probe for the bcr gene to
confirm the clonal origin of blast crisis in two
patients with CML. In addition, the results of these
molecular studies suggest that the fusion of c-abl to
the bcr gene - the molecular equivalent of the
Philadelphia chromosome, has already occurred at
the level of the pluripotent stem cell.
Patients and methods
Patients
The first patient was a 20 year old female with
CML first diagnosed in July 1983. She remained in
chronic phase for approximately 9 months but
while being considered for bone marrow trans-
plantation in April 1984, was noted to be in blast
crisis. She was treated with high dose Ara-C but
sustained only a partial response. Marrow samples
harvested during the chronic and acute phase were
available for study.
The second patient was a 39 year old female who
was first diagnosed as having CML in 1976. She
was treated intermittently with Busulphan until
April 1984, when she developed lymphoid blast
crisis. Following remission induction, an allogeneic
bone marrow transplant was performed in July
1984, but blast crisis recurred in March 1985.
Samples of this patient's marrow obtained in
chronic phase prior to transplantation and during
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the second episode of blast crisis were available for
analysis. Both patients were Ph'-positive
throughout the entire course of their disease and
exhibited no additional cytogenetic abnormalities.
Methods
Sources of DNA DNA was prepared from
peripheral blood or bone marrow cells of patients
with CML either in chronic phase or during blast
crisis. DNA prepared from the bone marrow of
normal donors was used as a control.
Isolation ofDNA DNA was purified as previously
described (Gusella et al., 1980). In brief, cells were
washed twice in PBS, resuspended in TNE (IOmM
Tris/lOOmM NaCI/lmM EDTA pH 8.0) and added
to an equal volume of TNE containing proteinase
K (400 ugml -1) and 1% NaDod S04. The
suspension was incubated at 37°C for 4-16h. The
DNA was then extracted once with phenol/chloro-
form/isomylalcohol and several times with chloro-
form/isomylalcohol. The DNA was then precipitated
withisopropanolandresuspendedin10mMTris/lmM
EDTA, pH 7.5. The concentration of DNA was
determined by spectroscopy; the A260/A280 ratio was
1.8-2.0.
Southern blot analysis Genomic DNA was cut
with one of several restriction enzymes including
EcoR1, Bgl II, or Hind III. Digested DNA was
separated on 0.8% agarose gels and transferred
(Southern 1975) to nylon membranes. The filters
were hybridized in 0.75 M NaCl/0.075 M sodium
citrate, pH 7.0/0.1% NaDod S04/0.02% Ficoll/0.02%
bovine serum albumin/0.02% polyvinyl-pyrroli-
done/50% formamide/10% dextran sulphate
containing sonicated salmon sperm (200pgml-1)
and radioactive probe (5 x 106cpmml-1).
Hybridization was at 42°C for 24h. Filters were
then washed thoroughly to high stringency and
autoradiographed for varying times at -70°C with
the aid of an intensifying screen.
Probes Several probes were used
experiments. A 1.2kb human bcr
fragment (see Figure 1 for restriction
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subcloned into a pSP vector construct immediately
downstream of the bacteriophage SP6 promotor
(Oncogene Science, Mineola, NY, USA). This probe
recognizes the 'break point cluster region' which is
a 5.8kb in length region on chromosome 22. The Jh
probe was a 3 kb cloned Eco Ri - Hind III
restriction fragment that recognizes the J and
adjoining intervening sequence regions of the
immunoglobulin heavy chain gene. The probes were
radiolabelled by nick translation with (a-32P)d CTP
(Rigby et al., 1977) to a specific activity of
108 cpmjg'- DNA.
Surface marker studies A panel of fluorescent
monoclonal antibodies was used to study the cell-
surface phenotype of leukaemic cells obtained
during the acute phase of CML in each patient.
Results
A panel of fluorescent monoclonal antibodies was
used to determine the surface phenotype of
leukaemic blasts harvested during the acute phase
of each patient's illness. The results of this analysis
are shown in Table I. In patient no. 1, blasts made
up 64% of the cells examined by light microscopy.
However the majority of blasts examined did not
react significantly with any of the antibodies tested.
OKM-1, M02, and MY-906 recognize myeloid
differentiation antigens but these markers were only
identified on a small (15%) subpopulation of cells,
defined mainly by OKM-1. In this patient,
lymphoid antigens such as cALLa, Tdt, cIgM were
virtually undetectable. In the second patient, blasts
represented 88% of the total cell population and in
this case, the cells were predominantly lymphoid in
type. Nearly all cells were Tdt and cALLa
(recognized by J5) positive and a majority (69%)
expressed the Ia antigen (Table I). Tdt may be
present on both T and B lymphocytes (Bollum,
1979) although Ta and cALLa expression
correspond to early stages of B cell differentiation
in which immunoglobulin heavy chain genes have
been rearranged (Korsmeyer et al., 1983). Marker
studies were not performed on the bone marrow
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Figure 1 Restriction map of the cloned region in which occurs is illustrated. The 1.2kb probe is indicated by
the hatched box. B=BAM H1; Bg=BgL 11; E=EcorRl; H=Hind III; K=Kpnl.MOLECULAR STUDIES IN CML 461
Table I Cell-surface phenotype of blast crises in
two patients with CML
Antibodya b Patient no. I Patient no. 2
OKM-1 15c
M02 2 <1
MY-906 10 0
J5 (cALLa)d 3 84
HLA-Dr (Ia) 5 69
Tdtd 0 88
clgMd 0 0
aThe antibodies listed are a representative list of
the 36 different antibodies that constitute the entire
panel. bOKM1, M02 and MY906 recognize
myeloid-associated antigens and J5, HLA-Dr, Tdt
and clgM, lymphoid antigens. cNumbers represent
the percentage of fluorescent cells in a field of 200.
dcALLa, Tdt and clgM represent the common
acute lymphoblastic leukaemia, terminal deoxy-
nucleotidyl transferase and cytoplasmic lgM
antigens respectively.
samples obtained during chronic phase. However, at
these times, blasts constituted less than 10% of the
total cell population (data not shown).
Immunoglobulin gene rearrangement
The results of the immunoglobulin gene
rearrangement studies are consistent with the
marker studies shown in Table I. Paired DNA
samples representing the chronic phase and blast
crisis in each patient were analyzed using Southern
blotting techniques. For these experiments, DNA
was cut with Eco RI and probed with Jh (Figure 2).
In the first patient, no evidence of immunoglobulin
heavy chain gene rearrangement was detected. Both
DNA samples (Figure 2, Lane B, C) displayed a
germ line configuration identical to the normal
control (Figure 2, Lane A). In the second patient a
comparison of DNA patterns revealed that
immunoglobulin heavy chain genes had retained
their germ line structure during the chronic phase
of CML (Figure 2, Lane D), but had rearranged
during blast crisis (Figure 2, Lane E). This latter
observation not only confirms the lymphoid nature
of blast crisis in this patient but assigns the blasts
to the B cell lineage (Korsmeyer et al., 1983). A
faint germ line band visible in the acute phase DNA
sample (Figure 2, Lane E) probably represents
residual myeloid cells.
BCR rearrangement
Paired DNA samples from each patient were cut
with Eco RI, Hind III or Bgl II and probed with a
1.2kb bcr restriction fragment. In both patients the
bcr gene had rearranged, although the patterns of
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Figure 2 Southern blot analysis of immunoglobulin
heavy chain genes. DNA was cut with EcoRl and
probed with the Jh probe. Lanes B,C and D, E
represent the chronic and acute phase DNA samples
of the first and second patients respectively. Lane A
was the normal control. The arrow illustrates the
germline bands. The size of the fragments is expressed
in kilobases.
rearrangement differed considerably. In Figure 3, in
which DNA was cut with EcoR1, patient no. 1
appeared to have a germ line band in both lanes
(Lanes B & C). However, when the appropriate
DNA samples were digested with Hind III, a new
band (Figure 4, Lanes A & B) representing
rearrangement of the bcr gene was observed. This
band was the same size in both the acute and
chronic phase DNA samples. In this case,
translocation of c-abl to chromosome 22 had not
involved the RI sites upstream of the Hind III
restriction sites. In the second patient, a new band
has appeared in both the acute and chronic phase
DNA samples (Figure 3, Lanes D & E) and as with
the first patient these appeared to be of an identical
size. When probing these filters with the bcr probe,
a germ line band is visible in each lane,462 J.R. ZALCBERG et al.
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Figure 3 Southern blot analysis of the bcr gene DNA
was cut with EcoRl and probed with the °bcr' probe.
Lanes B,C and D, E represent the chronic and acute
phase DNA samples of the first and second patient
respectively. Lane A represents the normal control.
The arrow illustrates the germline band. The size of
the fragments is expressed in kilobases.
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Figure 4 Southern blot analysis of the bcr gene.
DNA was cut with Hind III and probed with the °bcr'
probe. Lanes A and B represent the chronic and acute
phase DNA samples of patient no. 1. Lane C
represents the normal control. The size of the
fragments is expressed in kilobases.
corresponding to the normal unrearranged bcr gene
present on the uninvolved chromosome 22.
Discussion
This report describes two patients with Philadelphia
positive CML terminating in blast crisis. In the first
case (patient no. 1) the leukaemic blasts did not
express lymphoid or myeloid antigens (Table I) and
the immunoglobulin heavy chain genes (Figure 2)
were not rearranged. By contrast in the second
patient, as well as having rearranged their heavy
chain genes, the leukaemic blasts expressed several
lymphoid antigens normally only present during the
earliest stages of B-cell differentiation (Table I).
Thus, these patients have developed myeloid (based
on morphologic rather than phenotypic criteria)
and lymphoid blast crises respectively. Similar
findings were reported by Bakhshi et al. (1983) who
examined 18 cases of CML. Eight of the nine
episodes of lymphoid crisis had heavy chain
rearrangement whereas during the chronic myeloid,MOLECULAR STUDIES IN CML 463
myeloid blast and erythroid phases of CML, cells
were shown to have germ line immunoglobulin
genes.
Both patients described in this report had a
Philadelphia chromosome, the molecular equivalent
of which is thought to be the translocation of c-abl
to chromosome 22 with an associated structural
reorganization of the bcr gene (Heisterkamp et al.,
1985). Rearrangement of this gene (bcr) was
documented in both patients (Figures 3 & 4). We
have also observed varying patterns of rearrange-
ment of the bcr gene in three other patients with
lymphoid blast crisis (data not shown). At the
molecular level, the Ph' translocation is felt to
represent a random recombination event limited to
a 5.8kb region of chromosome 22 (Heisterkamp et
al., 1985). This conclusion was based on the absence
of sequence homology between different breakpoint
regions of individual patients with CML. A detailed
restriction enzyme analysis of 17 patients with
proven or probable (based on molecular studies)
Ph'-positive CML strongly supports this model of
random recombination (Groffen et al., 1984). In
that report, the majority of patients studied had
different patterns of bcr gene rearrangement.
Similarly in our own study, restriction enzyme
patterns varied between patients, but were identical
when comparing the chronic myeloid and blastic
phases within the one individual. Based on the
proposed model, the last observation suggests that
a common cell of origin gave rise to both the
chronic myeloid and blastic phases of CML in each
case.
In the second patient with lymphoid blast crisis
(Table I and Figure 2), the finding of identical bcr
restriction enzyme patterns (Figure 3, Lanes D &
E), not only suggests that the chronic myeloid and
blastic phases of CML were derived from a single
progenitor cell, but also that genetic recombination
has already occurred at the level of the pluripotent
stem cell. This concept extends the model proposed
by Fialkow et al. (1981). Based on the development
of clonally-derived (implied by isoenzyme studies)
Ph'-negative lymphoid cell lines from a patient with
Ph'-positive CML, Fialkow suggested that the Ph'
abnormality occurred as a secondary event in
descendants of haemopoietic stem cell precursors.
The molecular studies described herein do not
preclude this hypothesis but based on a model of
random recombination, the data presented suggest
that rearrangement of the bcr gene - the molecular
equivalent of the Ph' translocation, has already
occurred in stem cells capable of myeloid or
lymphoid differentiation. Evidence of the Ph'
abnormality at the level of the pluripotent stem cell,
in conjunction with recent data suggesting that the
fusion of the bcr and abl genes in CML results in
the production of a novel 8.7kb mRNA
(Shtivelman et al., 1985), implies that this marker
may be critical in the pathogenesis of CML.
However these results do not prove that the 9:22
translocation occurred during the initial trans-
formation event. It is also of interest that since the
same bcr-c-abl rearrangement is seen in both the
acute and chronic phases in the same patient,
progression into blast crisis does not appear to
depend on further molecular alteration at the bcr-c-
abl locus. Further molecular studies are underway
to define the exact role of the bcr and c-abl
oncogenes in the biology of CML.
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